1. |
Kim H, Lee SB, Nam SJ, et al. Survival of breast-conserving surgery plus radiotherapy versus total mastectomy in early breast cancer. Ann Surg Oncol, 2021, 28(9): 5039-5047.
|
2. |
Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol, 2010, 11(10): 927-933.
|
3. |
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019年版). 中国癌症杂志, 2019, 29(8): 609-679.
|
4. |
Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol, 2019, 30(10): 1541-1557.
|
5. |
Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA, 2011, 305(6): 569-575.
|
6. |
Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA, 2017, 318(10): 918-926.
|
7. |
Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2019, 30(8): 1194-1220.
|
8. |
Giuliano AE, Ballman K, McCall L, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial. Ann Surg, 2016, 264(3): 413-420.
|
9. |
Paluch-Shimon S, Cardoso F, Partridge AH, et al. ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). Ann Oncol, 2020, 31(6): 674-696.
|
10. |
Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin, 2006, 56(1): 37-47.
|
11. |
刘淼, 王殊, 彭媛, 等. ACOSOG Z0011试验标准用于中国前哨淋巴结阳性乳腺癌患者以避免腋窝淋巴结清扫的可行性研究. 中国癌症杂志, 2015, 25(2): 135-140.
|
12. |
刘淼, 王殊, 杨后圃, 等. ACOSOG Z0011试验结果对中国乳腺外科医生临床实践影响的调查. 肿瘤防治研究, 2016, 43(1): 48-53.
|
13. |
Livingston EH, Li HC. Breast cancer surgery: less is more. JAMA, 2017, 318(10): 909-911.
|
14. |
Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med, 2018, 379(2): 111-121.
|
15. |
Ong CT, Thomas SM, Blitzblau RC, et al. Patient age and tumor subtype predict the extent of axillary surgery among breast cancer patients eligible for the American College of Surgeons Oncology Group Trial Z0011. Ann Surg Oncol, 2017, 24(12): 3559-3566.
|
16. |
Poodt IGM, Spronk PER, Vugts G, et al. Trends on axillary surgery in nondistant metastatic breast cancer patients treated between 2011 and 2015: A dutch population-based study in the ACOSOG-Z0011 and AMAROS era. Ann Surg, 2018, 268(6): 1084-1090.
|
17. |
Liu M, Wang S, Cui S, et al. The feasibility of the ACOSOG Z0011 criteria to Chinese breast cancer patients: a multicenter study. Sci Rep, 2015, 5: 15241. doi: 10.1038/srep15241.
|
18. |
Nayyar A, Strassle PD, Shen MR, et al. Survival analysis of early-stage breast cancer patients undergoing axillary lymph node dissection and sentinel lymph node dissection. Am J Surg, 2018, 216(4): 706-712.
|
19. |
Nowikiewicz T, Zegarski W, Pagacz K, et al. Does the presence of sentinel lymph node macrometastases in breast cancer patients require axillary lymph node dissection? Single-center analysis. Breast J, 2018, 24(5): 724-729.
|
20. |
Wang J, Mittendorf EA, Sahin AA, et al. Outcomes of sentinel lymph node dissection alone vs. axillary lymph node dissection in early stage invasive lobular carcinoma: a retrospective study of the surveillance, epidemiology and end results (SEER) database. PLoS One, 2014, 9(2): e89778. doi: 10.1371/journal.pone.0089778.
|
21. |
Peristeri DV, Harissis HV. Axillary lymph node dissection vs sentinel biopsy only among women with early-stage breast cancer and sentinel node metastasis: a systematic review and meta-analysis. Breast J, 2021, 27(2): 158-164.
|
22. |
Jagsi R, Chadha M, Moni J, et al. Radiation field design in the ACOSOG Z0011 (Alliance) trial. J Clin Oncol, 2014, 32(32): 3600-3606.
|
23. |
Colleoni M, Sun Z, Price KN, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials Ⅰ to Ⅴ. J Clin Oncol, 2016, 34(9): 927-935.
|
24. |
Dutta SW, Volaric A, Morgan JT, et al. Pathologic evaluation and prognostic implications of nodal micrometastases in breast cancer. Semin Radiat Oncol, 2019, 29(2): 102-110.
|
25. |
Wu P, Zhao K, Liang Y, et al. Validation of breast cancer models for predicting the nonsentinel lymph node metastasis after a positive sentinel lymph node biopsy in a chinese population. Technol Cancer Res Treat, 2018, 17: 1533033818785032. doi: 10.1177/1533033818785032.
|
26. |
Loza CM, Mandó P, Ponce C, et al. Predictive factors for non-sentinel lymph node metastasis in patients with ACOSOG Z0011 Criteria. Breast Care (Basel), 2018, 13(6): 434-438.
|
27. |
Qiu PF, Liu JJ, Wang YS, et al. Risk factors for sentinel lymph node metastasis and validation study of the MSKCC nomogram in breast cancer patients. Jpn J Clin Oncol, 2012, 42(11): 1002-1007.
|